Neuralink receives FDA Breakthrough Device Designation for Blindsight
Evidence notes
- The visual prosthesis program is intended to restore visual perception for people with severe vision loss.
- The designation supports faster development and review but does not represent market approval.
Company context
Neuralink develops implantable brain-computer interfaces and the R1 surgical robot used to place ultra-fine electrode threads.